文献库搜索 | GeneLibs

Li(Xiaolei),Tao(Junyan),Cigliano(Antonio),... Oncotarget 2016-04-05

...PIK3CA (PIK3CAH1047R) and Yap (YapS127A) in the mouse liver using hydrodynamic transfection (PIK3CA/Yap). In addition, s...

Hanusch(Claus),Schneeweiss(Andreas),Loibl(... Clin Cancer Res 2016-04-19

...PIK3CA tumor mutations (P = 0.363). Clinical responses were seen in 96.3% of 54 evaluable patients, and breast conservin...

Takenaka(Masataka),Saito(Motonobu),Iwakawa... Int J Oncol 2016-01-26

...PIK3CA (25.0%), KRAS (13.9%), ERBB2 (4.3%), PTEN (2.8%), RB1 (2.8%), CDKN2A (2.8%), AKT1 (1.4%), CTNNB1 (1.4%) and NRAS ...

Miura(John T),Xiu(Joanne),Thomas(James),Ge... Cancer Biol Ther 2016-03-01

...PIK3CA (5.1%). IHC of TOP2A was high in 76% of cases, TOPO1 in 51% and SPARC in 25%; low IHC of ERCC1 was seen in 65%, R...

Ha(Sang Yun),Choi(So-Jung),Cho(Jong Ho),Ch... Oncotarget 2016-01-19

...PIK3CA, ERBB2, BRAF, ROS1, and RET genesoccurred in 7%, 4%, 2.5%, 1.5%, 1%, 1%, and 1% of cases, respectively. Thus, 79%...

Rusan(Maria),Li(Yvonne Y),Hammerman(Peter ... Clin Cancer Res 2016-03-31

...PIK3CA mutations (and aberrations in other members of the PI3K pathway), alterations in receptor tyrosine kinases (prima...

Nuciforo(P G),Aura(C),Holmes(E),Prudkin(L)... Ann Oncol 2016-04-05

...PIK3CA mutation) with total pathological complete response (tpCR) at surgery, event-free survival (EFS), and overall sur...

Normanno(N),Rachiglio(A M),Lambiase(M),Mar... Ann Oncol 2016-04-21

...PIK3CA mutations, in order to assess potential clinical implications.,Tumor samples (n = 182) from the CAPRI-GOIM trial ...

Suzuki(Masaki),Yazawa(Takuya),Ota(Satoshi)... Histopathology 2016-10-20

...PIK3CA mutations were identified in 20%, 0%, 0% and 7% of the tumours, respectively.,Lung adenocarcinomas with H-FLAC fe...

Schwaederle(Maria),Daniels(Gregory A),Picc... Mol Cancer Ther 2016-04-12

...PIK3CA (12%). The median number of alterations per patient was 3 (range, 0-16). Nineteen patients (4%) had no alteration...